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INTRODUCTION
While BK virus presents a well-known cause of renal 
allograft  dysfunction, far fewer cases describing John 
Cunningham (JC) virus as a culprit have been report-
ed. Both of the viruses, along with several others de-
scribed, belong to the same group of species-specifi c 
polyomaviruses (1). Th ese viruses are ubiquitous with 
seroprevalence in humans ranging from 65% to 90% 
for BK virus and 44%-92% for JC virus (2). JC virus 
primary infection usually occurs during the fi rst years 
of life and is most commonly asymptomatic. Aft er pri-
mary viremia, JC virus latently infects kidney epithe-
lial cells and may be found in the urine (3,4). Some 
authors suggest that JC virus may develop persistent 
infection in kidneys and lymphoid organs (5). Th e vi-
rus is also neurotropic and may cause progressive mul-
tifocal leukoencephalopathy (5,6). While BK virus-as-
sociated nephropathy (BKVAN) is relatively common, 
manifested in up to 10% of renal transplant recipients 
(1), JC virus-associated nephropathy (JCVAN) is seen 
far less oft en; a review from 2016 (7) has reported only 
20 cases described in the English-language literature 
with the fi rst one in 2003 (8). 
CASE REPORT
A 68-year-old male with a history of alcoholism and 
essential hypertension was diagnosed with focal seg-
mental glomerulosclerosis and IgG kappa monoclonal 
gammopathy of unknown signifi cance in 2008. He was 
started on hemodialysis in 2015 and received a kidney 
transplant from a deceased donor in July 2017. He re-
ceived basiliximab for induction and tacrolimus, my-
cophenolate mofetil and steroids for maintenance. Th e 
post-transplantation period was complicated with uri-
nary tract infections and spontaneous vertebral frac-
tures, which were treated with denosumab. Addition-
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ally, he had leukopenia, which demanded decreased 
doses of mycophenolate. In August 2018, serum creat-
inine increased from the baseline value of 150 μmol/L 
with proteinuria of 0.6 g/day to creatinine 209 μmol/L 
and proteinuria of 4 g/day, so renal biopsy was per-
formed. Donor specifi c antibodies were negative. Th e 
patient’s blood and urine samples were analyzed em-
ploying the real-time polymerase chain reaction (RT-
PCR) by the LightMix Kit for detection of Polyoma-
viruses. Th e blood samples were negative for both BK 
virus and JC virus DNA, but in urine >106copies of JC 
virus DNA were detected with negative BK virus DNA.
Th e biopsy specimen showed pathological fi ndings that 
were described as a Banff  score class III polyomavi-
rus-associated nephropathy (pvl1, ci3) along with fi nd-
ings described as chronic parenchymal changes, which 
may have been the consequences of previous bacterial 
infections. Also, epithelial polymorphy with nuclear 
hyperchromasia and intranuclear viral inclusions was 
visible in some tubules, which also displayed positive 
immunohistochemical reaction to SV40 antigen (Fig-
ures 1 and 2), common to both JC and BK viruses. In 
order to prove JC virus as a pathogen, RT-PCR analysis 
of the biopsy sample was performed. It detected >106 
copies of JC virus per mL with negative BK virus DNA. 
Th e diagnosis of JCVAN was established. 
Fig. 1. Micrograph of the biopsy sample showing papyloma 
virus-associated nephropathy pathology.
Fig. 2. Positive SV40+ staining.
At the time, his immunosuppressive therapy included 
tacrolimus monohydrate at a dose of 1.75 mg (through 
level 4.8 ng/mL), mycophenolate mofetil 2x500 mg 
and 10 mg of prednisone. Aft er the diagnosis, immu-
nosuppressive therapy remained the same but was 
lowered to 1 mg/2x500 mg/5 mg, respectively. Intra-
venous immunoglobulins (IvIg) (2 g/kg) were also ap-
plied, divided over four days. Aft er IvIg therapy, his re-
nal parameters began to fall towards the earlier values. 
He was released home on day 22 of his hospital stay. 
Not a month aft er discharge from the hospital, he suf-
fered yet another urosepsis but recovered quickly. His 
current kidney function is steady with serum creati-
nine levels of 145 μmol/L, proteinuria 1.5 g/day and 
immunosuppressive therapy consisting of tacrolimus 
(target through level around 3-4 ng/mL) and predni-
sone 5 mg.
DISCUSSION
John Cunningham virus is a well-known cause of pro-
gressive multifocal leukoencephalopathy in immu-
nocompromised patients, such as HIV-infected with 
low CD4+ count (5). It is far less common for JC virus 
to cause polyomavirus-associated nephropathy. In a 
prospective cohort study by Drachenberg et al., 0.9% 
of kidney transplant patients were diagnosed with 
JCVAN, while studies on BK virus report on 1%-10% 
incidence of BKVAN in kidney transplant population 
(1,8-12). 
Th e most prominent problems with JCVAN are di-
agnosis and screening. Although Drachenberg et al. 
displayed a strong association between JC viremia and 
JCVAN, it was not present in all of the patients as 2 
out of 6 patients were not proven to have JC viremia 
at the time of the study (10). Other cases of JCVAN 
without PCR-proven JC-viremia have also been not-
ed (13). John Cunningham viremia may yet prove to 
be useful in diagnosing JCVAN, as a vast number of 
patients with JC viremia do develop JCVAN (4,10). 
Some authors suggest that JC viruria is not a helpful 
screening tool for detection of JCVAN, as its incidence 
is not signifi cantly increased in kidney-transplant pa-
tients; the more so, it does not appear to be increasing 
at all in immunosuppressed patients, unlike the BKV 
viruria (14). Regarding the viral quantitative load, it is 
still unclear whether it does increase in the immuno-
suppressed patients (4). 
Th e most common immunosuppression used in our 
institution for kidney transplant patients is a combina-
tion of tacrolimus, mycophenolate mofetil and pred-
nisone. Querido et al. proposed some risk factors for 
Arrows indicate cytopathic effect of JC virus (hematoxylin-eosin, X40).
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development of JCVAN in kidney transplant patients 
including the use of mycophenolate mofetil and tac-
rolimus as immunosuppressive agents (15). Besides 
immunosuppression, additional risk factors found 
in our patient were male gender and deceased donor 
transplantation. He neither received anti-thymocyte 
globulin induction therapy nor had acute rejection 
episodes. 
We reversed the course of JCVAN successfully with 
high doses of intravenous immunoglobulins and re-
duction of immunosuppressive therapy. Some cases 
of JCVAN have been reported to improve aft er con-
version from tacrolimus to everolimus (15), which 
was not possible in our patient due to proteinuria. 
Attempts to improve glomerular fi ltration rate with 
tacrolimus to cyclosporine have also been made, as 
well as some antiviral agents and adding lefl unomide 
to therapy (11,13).
CONCLUSION
Available data on the diagnosis and treatment of 
JCVAN are scarce. Our case demonstrated that due to 
biology similarities of JC virus and BK virus, experi-
ences and methods used in the treatment of BKVAN 
may be employed in the treatment of JCVAN. 
R E F E R E N C E S
1. Pinto M, Dobson S. BK and JC virus: a review. J Infect 
2014; 68(Suppl1): S2-S8.
2. Knowles WA. Discovery and epidemiology of the human 
polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp 
Med Biol 2006; 577: 19-45.
3. Elia F, Villani S, Ambrogi F, et al. JC virus infection is 
acquired very early in life: evidence from a longitudinal sero-
logical study. J Neurovirol 2017; 23(1): 99-105.
4. Delbue S, Ferraresso M, Ghio L, et al. A review on JC 
virus infection in kidney transplant recipients. Clin Dev Immu-
nol 2013; 2013: 1-7.
5. Assetta B, Atwood WJ. Th e biology of JC polyomavirus. 
Biol Chem 2017; 398: 839-55.
6. Kirincich J, Basic-Jukic N, Radic J, Lovric-Kujundzic S, 
Kastelan Z. A kidney transplant recipient with fulminant pro-
gressive multifocal leukoencephalopathy-immune reconstitu-
tion infl ammatory syndrome: a rare clinical outcome and re-
view of the literature. Exp Clin Transplant 2020; 18(2): 242-6.
7. Trofe-Clark J, Sawinski D. BK and other polyomaviruses 
in kidney transplantation. Semin Nephrol 2016; 36(5): 372-85.
8. Kazory A, Ducloux D, Chalopin J-M, Angonin R, Fonta-
niere B, Moret H. Th e fi rst case of JC virus allograft  nephropa-
thy. Transplantation 2003; 76(11): 1653-5.
9. Lautenschlager I, Jahnukainen T, Kardas P et al. A case 
of primary JC polyomavirus infection-associated nephropathy. 
Am J Transplant 2014; 14(12): 2887-92.
10. Drachenberg CB, Hirsch HH, Papadimitriou JC et al. 
Polyomavirus BK versus JC replication and nephropathy in re-
nal transplant recipients: a prospective evaluation. Transplanta-
tion 2007; 84(3): 323-30.
11. Yang D, Keys B, J. Conti D et al. JC polyomavirus ne-
phropathy, a rare cause of transplant dysfunction: case report 
and review of literature. Transpl Infect Dis 2017; 19(2): e12654.
12. Wen M, Wang C, Wang M et al. Association of JC virus 
with tubulointerstitial nephritis in a renal allograft  recipient. J 
Med Virol 2004; 72(4): 675-8.
13. Janphram C, Worawichawong S, Disthabanchong S, Su-
methkul V, Rotjanapan P. Absence of JC polyomavirus (JCPyV) 
viremia in early post-transplant JCPyV nephropathy: a case re-
port. Transpl Infect Dis 2017; 19(6): 1-4.
14. Randhawa P, Uhrmacher J, Pasculle W et al. A compar-
ative study of BK and JC virus infections in organ transplant 
recipients. J Med Virol 2005; 77(2): 238-43.
15. Querido S, Jorge C, Sousa H et al. JC polyomavirus ne-
phropathy confi rmed by using an in-house polymerase chain 
reaction method. Transpl Infect Dis 2015; 17(5): 732-6.
M. Banić, M. Ćorić, V. Furić-Čunko, M. Mokos, I. Jurić, N. Bašić-Jukić
John Cunningham virus-associated nephropathy in a kidney transplant recipient
Acta Med Croatica, 74 (2020) 245-248
248
Dok je John Cunningham (JC) virus dobro poznati uzročnik progresivne multifokalne encefalopatije, dosad je opisan kao 
uzročnik nefropatije u tek nekoliko slučajeva. Prikazujemo bolesnika s transplantiranim bubregom koji se prezentirao prote-
inurijom i porastom serumskog kreatinina. Biopsijom presatka je dokazana poliomavirusna nefropatija. Uporabom lančane 
reakcije polimeraze BK virus i JC virus su bili negativni u krvi, u mokraći je BK virus bio negativan, a JC virus pozitivan, dok 
je iz bioptata dokazano više od 106 kopija DNA JC virusa, čime smo potvrdili dijagnozu nefropatije presatka uzrokovane 
JV virusom. Bolesnik je liječen intravenskim imunoglobulinima uz smanjivanje intenziteta imunosupresije. Ovaj bolesnik 
potvrđuje da JC virus može uzrokovati značajne promjene u bubrežnom presatku i da ga treba uključiti u diferencijalnu 
dijagnozu pogoršanja funkcije presatka.
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